Buchumschlag

The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer

The prognosis of patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC) is poor. There is no standard treatment available. Emerging evidence suggests a major role for antiangiogenic treatment modalities in EOC, in particular in combination with the metronomic application of low...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Eichbaum, Michael H. R. (VerfasserIn) , Mayer, Christine (VerfasserIn) , Eickhoff, Regina (VerfasserIn) , Bischofs, Esther (VerfasserIn) , Gebauer, Gerhard (VerfasserIn) , Fehm, Tanja (VerfasserIn) , Lenz, Florian (VerfasserIn) , Fricke, Hans-Christian (VerfasserIn) , Solomayer, Erich (VerfasserIn) , Fersis, Nikos (VerfasserIn) , Schmidt, Marcus (VerfasserIn) , Wallwiener, Markus (VerfasserIn) , Schneeweiss, Andreas (VerfasserIn) , Sohn, Christof (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 20 October 2011
In: BMC cancer
Year: 2011, Jahrgang: 11, Pages: 1-9
ISSN:1471-2407
DOI:10.1186/1471-2407-11-453
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-11-453
Volltext
Verfasserangaben:Michael Eichbaum, Christine Mayer, Regina Eickhoff, Esther Bischofs, Gerhard Gebauer, Tanja Fehm, Florian Lenz, Hans-Christian Fricke, Erich Solomayer, Nikos Fersis, Marcus Schmidt, Markus Wallwiener, Andreas Schneeweiss and Christof Sohn
Beschreibung
Zusammenfassung:The prognosis of patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC) is poor. There is no standard treatment available. Emerging evidence suggests a major role for antiangiogenic treatment modalities in EOC, in particular in combination with the metronomic application of low dose chemotherapy. The novel, investigational oral antiangiogenic agent pazopanib targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit is currently being studied in different tumour types and is already used as first line therapy in recurrent renal cell carcinoma. A combined therapy consisting of pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, pretreated EOC.
Beschreibung:Gesehen am 08.04.2022
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-11-453

Ähnliche Einträge